论文信息 - P.0449 Evaluation of IGF-1 as a novel theranostic biomarker for schizophrenia - 字舞流文

P.0449 Evaluation of IGF-1 as a novel theranostic biomarker for schizophrenia

H. Yesilkaya | M. İlnem | D. İpekçioğlu | M. Şen | Ş. Gıca

[1] O. Howes,et al. Schizophrenia-An Overview. , 2020, JAMA psychiatry.

[2] N. Pivac,et al. Theranostic Biomarkers for Schizophrenia , 2017, International journal of molecular sciences.

[3] M. Owen,et al. Schizophrenia , 2016, The Lancet.

[4] E. Bézard,et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification? , 2014, Progress in Neurobiology.

[5] S. R. Azua,et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6] H. Werner,et al. Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways , 2008, Archives of physiology and biochemistry.

[7] G. Venkatasubramanian,et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. , 2007, The American journal of psychiatry.

[8] N. Hooper,et al. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.